C21 Investments Inc.

CWLXFSEC EDGAR

Medicinal Chemicals & Botanical Products(A1)CIK: 831609

Concept	FY2025	FY2024	FY2023	FY2022
Revenues	$28.3M	$28.9M	$33.0M	$33.5M
Cost of Revenue	$17.1M	$15.5M	$14.2M	$15.4M
Gross Profit	$11.1M	$13.4M	$18.8M	$18.0M
Selling, General and Administrative Expense	$9.7M	$9.4M	$9.1M	$8.8M
Operating Income (Loss)	$1.5M	$4.0M	$9.8M	$9.2M
Interest Expense	$35.2K	$456.7K	$1.1M	$3.9M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$258.7K	$4.2M	$17.1M	-$1.6M
Income Tax Expense (Benefit)	$3.5M	$2.8M	$4.9M	$3.0M
Net Income (Loss) Attributable to Parent

Concept	FY2025	FY2024	FY2023	FY2022
Assets	$54.5M	$58.3M	$61.8M	$66.8M
Assets, Current	$7.2M	$8.6M	$10.3M	$11.3M
Accounts Receivable, after Allowance for Credit Loss, Current	$189.2K	$401.5K	$198.5K	$101.2K
Inventory, Net	$2.7M	$4.2M	$4.1M	$2.7M
Liabilities	$23.5M	$24.0M	$28.1M	$43.6M
Liabilities, Current	$14.2M	$15.0M	$16.0M	$15.2M
Accounts Payable, Current	$1.2M	$1.8M	$1.4M	$1.4M
Stockholders' Equity Attributable to Parent	$34.3M	$33.7M	$23.0M	$13.6M
Common Stock, Shares, Outstanding

Concept	FY2025	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	$3.3M	$6.0M	$8.4M	$8.5M
Net Cash Provided by (Used in) Investing Activities, Continuing Operations	-$121.6K	-$442.3K	-$2.6M	-$1.2M
Net Cash Provided by (Used in) Financing Activities, Continuing Operations	-$2.7M	-$6.6M	-$7.7M	-$3.7M
Payments to Acquire Property, Plant, and Equipment	$521.6K	$442.3K	$2.6M	$227.8K
Payments for Repurchase of Common Stock	$0.00	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)